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Background: Anaplastic lymphoma kinase (ALK), which is a receptor tyrosine kinase, is essentially and transiently
expressed in the developing nervous system. Recently, the deregulated expression of full-length ALK has been
observed in some primary solid tumors, but little is known about its involvement in the tumorigenesis of uterine
carcinosarcomas (UCSs). Here we examined the functional role of the ALK gene in UCSs.
Methods: Regulation and function of the ALK gene were assessed using two endometrial carcinoma cell lines.
Expression of ALK and its related molecules were also investigated using clinical samples of UCSs.
Results: In cell lines, ALK promoter activity was significantly increased by transfection of Sox11 and N-myc, which are
known to contribute to neuronal properties. Cells stably overexpressing full-length ALK showed an enhancement of
EMT properties mediated by TGF-β1 and HGF, along with an increase in phosphorylated (p) Akt and nuclear p65.
Overexpression of p65 also led to transactivation of Twist1 gene, known as an EMT inducer. Finally, treatment of the
stable ALK-overexpressing cells with doxorubicin resulted in inhibition of apoptosis with progressive increase in the
expression ratio of both pAkt and bcl2 relative to total Akt and bax, respectively. In clinical samples, strong cytoplasmic
ALK immunoreactivity and mRNA signals without rearrangement or amplification of the ALK locus were frequently
observed in UCSs, particularly in the sarcomatous components. Further, ALK IHC score was found to be positively
correlated with Sox11, N-myc, Twist1, and bcl2 scores.
Conclusion: ALK-related signal cascades containing Akt, NF-κB, Twist1, and bcl2 may participate in initial signaling for
divergent sarcomatous differentiation driven from carcinomatous components in UCSs through induction of the EMT
process and inhibition of apoptotic features.
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Uterine carcinosarcomas (UCSs), previously referred to as
malignant mixed mullerian tumors, are aggressive neo-
plasms with biphasic growth of high-grade carcinomatous
and sarcomatous elements, and only account for approxi-
mately 2–5% of all malignancies of the uterine corpus
[1, 2]. The most common epithelial components are the
serous type followed by endometrioid type, while the
sarcomatous component is composed of homologous* Correspondence: msaegusa@med.kitasato-u.ac.jp
Department of Pathology, Kitasato University School of Medicine, 1-15-1
Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeor heterologous tissues [3, 4]. Recent studies revealed
that most, but not all, UCSs are derived from a single
epithelial cell, supporting the idea that UCSs represent
metaplastic carcinomas [3, 5].
The anaplastic lymphoma kinase (ALK) gene, located
on chromosome 2p23, is highly homologous to that of
leukocyte tyrosine kinase (LTK) and further belongs to
the insulin receptor superfamily of receptor tyrosine
kinases (RTK) [6–10]. Full-length ALK is specifically
expressed in the developing central and peripheral ner-
vous system during embryogenesis and is associated with
the balance of cell proliferation and differentiation [11–13].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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chromosomal rearrangements have been found in a subset
of lymphomas and lung carcinomas,[7, 14] recently,
deregulated expression of full-length ALK has also been
observed in some primary solid tumors derived from vari-
ous tissues [15].
Epithelial-mesenchymal transition (EMT) plays a cen-
tral role in converting both normal and neoplastic epi-
thelial cells into derivatives with a more mesenchymal
phenotype [16, 17]. A hallmark of EMT is loss of cell-
cell adhesion molecules, down-regulation of epithelial
differentiation markers, and transcriptional induction of
mesenchymal markers [18]. Snail, Slug, and Twist, all
repressors of the E-cadherin gene, are also involved in
the process [19–22]. Interestingly, carcinosarcomas are
considered to represent a true example of complete
EMT [23, 24].
The oncogenic role of ALK is mediated by interactions
with downstream molecules that trigger substantial
intracellular signaling cascades, and is closely associated
with EMT properties [25–28]. We therefore hypothe-
sized that ALK may contribute to the determination of
the phenotypic characteristics of UCS cells through
regulation of its downstream transduction cascades that
pertain to the EMT process. To test this, we hereby in-
vestigated the expression of ALK, as well as the profiles
of its related molecules, using endometrial carcinoma
(Em Ca) cell lines and clinical UCS samples.
Methods
Plasmids and cell lines
Full-length cDNA of human ALK, c-myc, and N-myc
(Open Biosystems, Huntsville, AL, USA) were subcloned
into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). The
human ALK promoter between −2056 and +30 bp and the
human N-myc promoter encompassing −221 to +1312 bp
(where +1 represents the transcription start site) were
amplified by polymerase chain reaction (PCR) and were
subcloned into the pGL-3B vector (Promega, Madison,
WT, USA). The human Twist 1 promoter (GenBank acces-
sion number NG008114) between −1085 to +350 bp was
also cloned using similar procedures. A series of 5’-trun-
cated promoter constructs of ALK and Twist1 genes were
generated by PCR-based methods. Site-directed mutagen-
esis in putative E1- and E2-boxes in the ALK promoter
region was also carried out using the PrimeS-TAR Muta-
genesis Basal kit (Takara Bio, Shiga, Japan). The pGL3B-
Snail (containing the −1109/+36 sequence), pGL3B-Slug
(−2125/-235 bp), pcDNA3.1-Sox2, pcDNA3.1-Sox3, pcD
NA3.1-Sox4, pcDNA-Sox5, pcDNA3.1-Sox6, pcDNA3.1-
Sox7, pcDNA3.1-Sox9, pcDNA3.1-Sox11, pcDNA3.1-
Sox17, pcDNA3.1-mouse p65, and pNF-κB were also
employed as described previously [29, 30]. Two sets of
short hairpin oligonucleotides directed against ALK weredesigned using the siDirect version 2 software. Single-
stranded ALK oligonucleotides were first annealed and
then cloned into BamHI-EcoRV sites of the RNAi-Ready
pSIREN-RetroQ vector (Takara, Shiga, Japan), according
to the manufacturer’s instructions. The sequences of PCR
primers used in this study are listed in Table 1.
The Em Ca cell lines, Ishikawa and Hec251 cells, were
maintained in Eagle’s MEM with 10% bovine calf serum.
The full-length ALK expression plasmid or empty vec-
tor was transfected into Hec251 cells, and the stable
overexpressing clones were established as described
previously [31].
Antibodies and reagents
Anti-ALK, anti-phospho-Akt at serine (Ser) 473 (pAkt),
anti-Akt, anti-Slug, anti-Snail, and anti-cleaved caspase 3
antibodies were purchased from Cell Signaling (Danvers,
MA, USA). Anti-Sox11 and anti-β-actin antibodies and
doxorubicin were obtained from Sigma-Aldrich Chemicals
(St. Louis, MO, USA). Anti-N-myc, anti-Twist1, and anti-
Histone H1 antibodies were from Abcam (Cambridge,
MA, USA). Anti-NF-κB/p65, anti-p27kip1, and anti-bax
antibodies were from BD Biosciences (San Jose, CA, USA).
Anti-bcl-2 and anti-p21waf1 antibodies were from Dako
(Glostrup, Denmark). Anti-cyclin A antibody was from
Novocastra (Newcastle, UK). Recombinant human tumor
necrosis factor (TNF)-α, transforming growth factor
(TGF)-β1, and hepatocyte growth factor (HGF) were pur-
chased from R&D Systems (Minneapolis, MN, USA).
Transfection
Transfection was carried out using LipofectAMINE
PLUS (Invitrogen), in duplicate or triplicate as described
previously [26–28]. Luciferase activity was assayed as de-
scribed previously [29–31]. The two siRNAs against NF-
κB/p65 or the negative control were transfected using
the siPort NeoFx transfection agent (Ambion, Austin,
TX, USA), according to the manufacturers’ instructions.
Real-time reverse-transcription (RT)-PCR
cDNA was synthesized from 2 μg of total RNA. For
quantitative analysis, real-time RT-PCR was carried out
using the Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) with specific primers
(Table 1). Fluorescent signals were detected using the ABI
7500 real-time PCR system, and data were analyzed using
the associated ABI 7500 System SDS software (Applied
Biosystems). Analysis of the GAPDH gene was also ap-
plied as internal control, as described previously [29–31].
Western blot assays
Total cellular proteins were isolated using RIPA buffer
[20 mM Tris–HCl (pH7.2), 1% Nonidet p-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate]. The nuclear
Table 1 Primer sequences used in the study
Assay Gene/region Sequence













Mutagenesis ALK E-box1 Forward 5'-GCTGTATAGTGGCGGGCGCCCAGGCAG-3'
Reverse 5'-GCCCGCCACTATACAGCTGGCTGAGCCGCGC-3'
ALK E-box2 Forward 5'-CAGGTATAGTGCGATCCAGCGGCTCTG-3'
Reverse 5'-GGATCGCACTATACCTGGGCGCCCGCCACTT-3'








ChIP ALK −126 Forword 5'-GCGGAGTTGGCTTGTGAGCC-3'
+12 Reverse 5'-TGCTACCACCGCTGCCGCC-3'
Twist 1 −101 Forward 5'-GGGGACTGGAAAGCGGAAAC-3'
+62 Reverse 5'-TGCAGAGCCCGCGAGGTGT-3'
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plasmic Extraction Reagents (Pierce Biotech., Rockford,
IL, USA). Aliquots of the proteins were resolved by
SDS-PAGE, transferred to PVDF membranes, and
probed with primary antibodies coupled to the ECL de-
tection system (Amersham Pharmacia Biotechnology,
Tokyo, Japan). The intensity of individual signals wasmeasured using ImageJ software version 1.41 (NIH,
Bethesda, MD, USA).
Flow cytometry
Cells were fixed using 70% alcohol and stained with pro-
pidium iodide (Sigma-Aldrich) for cell cycle analysis.
The prepared cells were analyzed by flow cytometry
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Pro software (BD Biosciences).
Chromatin immunoprecipitation (ChlP) assay
ChIP analysis was performed using the EpiXplore ChIP
assay kit (Clontech Laboratory, Mountain View, CA,
USA). Briefly, cells were cross-linked with formaldehyde
after transient transfection of pcDNA3.1-mouse p65.
Cell lysates were sonicated to shear DNA to lengths be-
tween 200 and 1000 bp, and then precipitated overnight
using anti-NF-κB/p65 antibody or mouse IgG as nega-
tive control, along with magnetic beads. After proteinase
K digestion, DNA was extracted and analyzed by PCR.
ChIP analysis was conducted with a reduction in the
number of cycles from 30 to 25, using four specific pri-
mer sets (Table 1).
Immunofluorescence
Hec251 cells stably overexpressing full-length ALK were
incubated with anti-ALK antibody. FITC-labeled anti-
rabbit IgG (Molecular Probes, Eugene, OR, USA) was used
as secondary antibody as described previously [26–28].
Clinical cases
We reviewed cases of comprehensively staged high-grade
endometrial adenocarcinomas from the patient records of
Kitasato University Hospital for the period from 1997 to
2015. According to the criteria of the 2014 World Health
Organization classification, [32] tumors were designated
as UCS if they had evidence of both malignant epithelial
(endometrioid, serous, or clear cell components) and mes-
enchymal (homologous or heterologous) elements. Endo-
metrioid adenocarcinomas with spindle elements and
hyalinized stroma were specifically excluded. Finally, a
total of 27 UCSs were investigated (Table 2). Of these, 20
cases had endometrioid components and 7 cases con-
tained non-endometrioid epithelial components, including
serous and clear types, while 21 and 6 cases showed hom-
ologous and heterologous mesenchymal elements, re-
spectively. All tissues were routinely fixed in 10% formalin
and processed for embedding in paraffin wax. Approval
for this study was given by the Ethics Committee of the
Kitasato University School of Medicine (B14–35).
Immunohistochemistry (IHC)
IHC was performed using a combination of the micro-
wave oven heating and polymer immunocomplex (Envi-
sion, Dako) methods. For immunohistochemical detection
of ALK, the ALK iAEP kit (Nichirei Biosciences, Tokyo,
Japan) was applied. Lung carcinoma tissues with ALK
overexpression due to a gene abnormality were used as
positive control.
For evaluation of IHC findings, scoring of nuclear or
cytoplasmic immunoreactivity was performed, on thebasis of the percentage of immunopositive cells and the
immunointensity with multiplication of the values of the
two parameters, as described previously [29–31]. ALK
immunopositive cells located in the carcinomatous, sar-
comatous, or both components were defined as epithe-
lial, stromal, or mixed type, respectively.In situ hybridization (ISH)
Riboprobes for ALK containing nucleotides 3946 to
4633 of the ALK gene were generated by in vitro tran-
scription using full length ALK cDNA, and ISH assays
were performed using the GenPoint Tyramide Signal
Amplification System (Dako) as described previously
[33]. ISH signal score were classified into four levels, as
follows: −, none; 1+, fewer than 10% positive cells; 2+,
10–30%; 3+, more than 30%. Samples with a score of ei-
ther 1+, 2+, or 3+ were considered as positive and—was
considered as negative.FIuorescence in situ hybridization (FISH)
For analysis of the ALK (2p23) locus, dual-color FISH
studies were conducted on 10 UCS cases with strong ALK
immunopositivity using the Vysis LSI ALK break-apart re-
arrangement probe (Abbott Molecular, Abbott Park, IL,
USA), according to the manufacturer’s instructions.Statistics
Comparative data were analyzed using the Mann-Whitney
U-test and the Spearman’s correlation coefficient. The cut-
off for statistical significance was set as p < 0.05.Results
Full-length ALK expression in UCS cases
Representative images of IHC findings for ALK are illus-
trated in Fig. 1a. Cytoplasmic immunoreaction was mainly
observed in both carcinomatous and sarcomatous compo-
nents of UCSs. ALK immunopositivity was evident in 11
(40.7%) of 27 UCS cases, including 3 (11.1%) of the epithe-
lial type, 7 (25.9%) of the stromal type, and one (3.7%) of
the mixed type (Table 2). In 21 UCS cases, positive signals
for ALK mRNA were detected in 15 (71.4%) cases, includ-
ing 4 (19%) of epithelial type, 5 (23.8%) of stromal type,
and 7 (33.3%) of mixed type (Fig. 1b and Table 2). The
observed ALK mRNA signals tended to be positively asso-
ciated with the IHC score, although it did not reach statis-
tical significance (Fig. 1c). Finally, FISH assay revealed no
rearrangement or amplification of the ALK locus in 5 UCS
cases with strong immunoreactivity (Fig. 1d and Table 2).
These findings indicated that overexpression of full-length
ALK at both mRNA and protein levels was frequently
observed in UCSs.
Table 2 Summary of the profiles of ALK and its related molecules in 27 uterine carcinosarcoma cases
ALK Sox11 N-myc pAkt Twist1 bcl2
Case Age Histology IHC ISH FISH IHC IHC IHC IHC IHC
No. (year) Ca Sa Ca Sa Ca Sa Ca Sa Ca Sa Ca Sa Ca Sa Ca Sa
UCS 1 59 Non-E Homo 0 0 1+ – a 2 0 0 0 2 0 8 0 12 2
UCS 2 60 Non-E Het (con) 0 0 – – a a a 0 0 a a a a a a
UCS 3 61 E Homo 0 0 a a a 0 0 0 0 2 0 4 0 0 0
UCS 4 81 E Het (con) 2 0 1+ − a 3 0 0 0 4 4 6 2 8 8
UCS 9 58 E Homo 0 0 N 3+ a a a a a a a a a 2 4
UCS 10 85 E Homo 0 0 3+ 3+ a 0 2 0 0 2 6 0 9 0 0
UCS 19 59 E Homo 0 0 − − a 0 0 0 0 4 4 3 12 0 0
UCS 12 76 E Homo 0 0 3+ N a 0 0 0 0 0 8 0 4 3 3
UCS 22 58 E Homo 0 0 − 2+ a 0 0 0 0 0 0 0 0 0 0
UCS 25 74 E Homo 0 2 1+ 1+ a a a a a a a a a 0 0
UCS 26 78 Non-E Het (con) 0 0 – 1+ a 0 0 0 0 2 2 0 0 a a
UCS 27 65 E Homo 0 2 1+ 1+ a 0 0 0 0 0 2 0 6 a a
UCS 29 73 E Het (Rha) 0 0 3+ – a 0 0 0 0 0 0 0 6 4 4
UCS 33 51 E Homo 0 12 a a – a a 0 0 2 0 a a a a
UCS 35 67 E Homo 0 4 3+ 2+ a 0 0 0 0 0 2 0 4 a a
UCS 36 57 E Homo 0 0 – N a 0 0 0 0 2 2 0 0 4 8
UCS 37 69 E Homo 0 6 – 3+ – 0 0 0 0 0 0 0 2 0 4
UCS 38 59 Non-E Homo 0 4 a a a 0 0 0 0 2 4 0 8 0 2
UCS 39 76 E Homo 0 4 2+ 2+ a 0 0 0 4 4 4 0 6 4 4
UCS 42 63 Non-E Homo 0 0 − − a 0 0 0 0 2 6 0 2 0 0
UCS 44 50 Non-E Homo 0 0 − 1+ a 0 0 0 0 2 2 0 6 0 0
UCS 45 75 E Het (Rha) 0 0 − − a 0 0 0 0 4 0 0 4 0 8
UCS 46 68 E Het (con) 0 0 2+ 1+ a 4 0 2 0 6 6 0 12 8 2
UCS 47 69 Non-E Homo 9 0 1+ 1+ − 4 8 a a 2 0 0 8 8 8
UCS 48 54 E Homo 0 0 a a a 0 0 0 0 0 0 0 2 0 4
UCS 51 59 E Homo 8 4 a a − 4 3 3 0 3 3 0 2 6 6
UCS 52 49 E Homo 6 0 a a − 6 0 0 0 0 0 12 0 a a
Abbreviations: No. number, Ca carcinomtous component, Sa sarcomatous component, IHC immunohistochemistry, ISH in situ hybridization, FISH Fluorescence in
situ hybridization, Non-Enon endometrioid, E endometrioid, Homo homologus, Het heterologous, con condrosarcoma, Rha rhabdomyosarcoma
anot examined; FISH -, no rearrangement ot amplification of ALK locus
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Since some Sox genes, as well as ALK, are essential
for development of general neuronal properties, [34]
we first examined the association between Sox factors
and ALK expression using Ishikawa cells. Transient
transfection of the longest ALK promoter constructs
(Fig. 2a), along with nine Sox factors, revealed that
Sox11, as well as Sox4 and Sox7, resulted in in-
creased activity of the ALK promoter, in contrast to
the inhibition by Sox5, Sox6, and Sox9 (Fig. 2b). Using
a series of 5’-truncated promoter constructs (Fig. 2a), we
found that deletion from −2056 to −416 bp had little effect
on induction of the promoter activity by Sox11, and the
shortest construct (−146/+30 bp), which lacks putativeSox-binding sites, still preserved the responsiveness to
Sox11 activation (Fig. 2c).
Transient transfection of N-myc, but not c-myc, re-
sulted in activation of the ALK promoter, in particular the
shortest reporter constructs (−146/+30 bp) (Fig. 2d). ChIP
assay also revealed that overexpression of N-myc caused
its recruitment to the region from −126 to +12 bp within
the ALK promoter (Additional file 1: Figure S1A). How-
ever, although four nucleotide alterations in E-boxes,
which are binding sites for N-myc, were introduced in the
shortest construct, changes in ALK promoter activity were
relatively minor (Additional file 1: Figure S1B and C).
Transfection of Sox11 also resulted in an increase in N-
myc mRNA expression, along with activation of its
Fig. 1 Full-length ALK expression in UCSs. a Staining by HE and IHC for ALK. Note the strong cytoplasmic ALK immunoreactivity in both carcinomatous
(indicated by a and arrow) and sarcomatous components (indicated by b and asterisk) (indicated by closed boxes and magnified in the insets) in
UCS51 (mixed type), UCS47 (epithelial type), and UCS33 cases (stromal type). Original magnification, ×100 and × 400 (inset). b Staining by HE
and ISH for ALK mRNA. Note the mRNA signals in carcinomatous (a) and sarcomatous cells (b) (indicated by closed boxes and magnified in the
insets) in UCS35 (mixed type), UCS29 (epithelial type), and UCS37 cases (stromal type). Original magnification, ×100 and × 400 (inset). c ALK IHC
score in ALK mRNA-positive (P) and −negative (N) UCS cases. The data shown are means ± SDs. d FISH analysis of UCS33 and UCS47 cases.
The interphase nuclei of both cases indicate absence of ALK rearrangement, in which the red and green signals remain fused (arrows)
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myc for induction of ALK promoter activity was not
observed (Fig. 2f ). These findings suggest that both
Sox11 and N-myc serve as positive transcriptional regula-
tors for the ALK gene in Em Ca cells, probably through
associations with the basic transcriptional machinery at
the promoter.
ALK enhances EMT phenotype by up-regulation of Twist1
through NF-κB/p65
The investigation of ALK signaling in UCSs was carried
out using two Em Ca, but not UCS, cell lines, since we
focused on an association between the functional roles of
ALK with induction of EMT features in the carcinomatous
components of UCSs. In addition, UCS cell lines are in
general very rare as compared to Em Ca cells.
To examine whether ALK expression is closely linked
to induction of EMT properties in Em Ca cells, two
independent Hec251 cell lines stably overexpressing full-
length ALK (H251-ALK#8 and #16) with strongcytoplasmic immunoreaction were established (Fig. 3a).
These two independent stable clones showed high pro-
liferation rates, particularly in the exponential growth
phase, along with decreased amounts of p21waf1, but
not cyclin A and p27kip1 (Additional file 2: Figure S2A
and B). H251-ALK#16 cells treated with TGF-β1 and
HGF, known as EMT inducers, demonstrated a dramat-
ically altered morphology toward a fibroblast-like ap-
pearance after 6 days as compared to mock-treated
cells, along with stabilization of exogenous full-length
ALK and increased expression of pAkt, nuclear p65, as
well as Twist1, but not Snail and Slug (Fig. 3b). NF-κB ac-
tivity as determined by a pNF-κB reporter construct was
also increased in H251-ALK#16 cells treated with TGF-β1
or HGF as compared to that of the mock cells
(Additional file 2: Figure S2C). In addition, transient
transfection of ALK induced increases in pAkt and nu-
clear p65 expression, but these effects were inhibited by
cotransfection of the shRNAs against ALK in Ishikawa
cells (Fig. 3c).
Fig. 2 Relationship of ALK expression with Sox11 and N-myc in UCSs. a Various ALK promoter constructs used in this study. b Ishikawa cells were
transfected with ALK promoter constructs, together with the indicated Sox genes. Relative activity was determined based on arbitrary light units
of luciferase activity normalized to pRL-TK activity. The activities of the reporter plus the effector relative to that of the reporter plus empty vector
are shown as means ± SDs. The experiment was performed in duplicate. c Ishikawa cells were transfected with various ALK promoter constructs,
together with Sox11. d Left: the shortest ALK reporter constructs, along with either c-myc or N-myc, were transfected into Ishikawa cells. Right: various
promoter constructs were used for evaluating transcriptional regulation of the ALK promoter by N-myc. e Left: Ishikawa cells were transfected
with N-myc promoter constructs, along with Sox11. Right: analysis of mRNA levels for the N-myc gene by real time RT-PCR in Ishikawa cells
after transfection of Sox11. f Ishikawa cells were transfected with ALK promoter constructs, together with Sox11 and N-myc
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reproducibly induce EMT, [35] we next examined whether
p65 can affect expression of Snail, Slug, and Twist1, all of
which are EMT-related genes. Treatment of Ishikawa
cells with TNF-α resulted in dramatically increased ex-
pression of Twist1 as compared to Snail and Slug, along
with stabilization of nuclear p65 (Fig. 3d). Transient
transfection of p65 resulted in a considerable increase
in Twist1 expression at both mRNA and protein levels,
along with increased activity of its promoter. However,
such associations were relatively minor for Snail and
Slug (Fig. 3e).
Next, analysis of an approximately 1000 bp fragment
upstream of the transcription start site in the Twist1
gene revealed six potential NF-κB/p65-binding elements
(5’-GGRNNYYCC-3’) (Fig. 4a). Using a series of 5’-trun-
cated promoter constructs (Fig. 4a), we found that dele-
tion from −1086 to −101 bp had little effect on induction
of the promoter activity by p65, whereas the −101/
+101 bp deletion appeared to have prevented binding of
p65 and reduced the promoter activity to a very low level
(Fig. 4b). Similar changes in the Twist1 promoter were
also observed by TNF-α treatment (Additional file 2:Figure S2D). ChIP assay also revealed that increased
amount of p65 caused its recruitment to the region of
−101 to +62 bp within the promoter lacking putative
NF-κB-binding sites (Fig. 4c). Finally, knockdown of en-
dogenous p65 resulted in a decrease in Twist1 expres-
sion in H251-ALK#16 cells (Fig. 4d), although pNF-κB
reporter activity was not altered by overexpression of
ALK (Additional file 2: Figure S2E). These findings sug-
gest that ALK indirectly contributes to NF-κB/p65-
meditaed Twist1 expression.Inhibition of apoptosis by ALK through stabilization of
pAkt and bcl2
Since it is known that Akt has potential anti-apoptotic
function, [36] we examined the contribution of the
ALK/Akt axis to susceptibility to apoptosis in UCSs.
Treatment of H251-ALK#16 with doxorubicin resulted
in a reduction in the quantity of apoptotic cells as com-
pared to mock-treated cells (Fig. 5a), along with
stabilization of exogenous full-length ALK (Fig. 5b). In
addition, the expression ratio of pAkt relative to total
(t) Akt progressively increased in a dose-dependent
Fig. 3 ALK/Akt/NF-κB axis in Em Ca cells. a Left: Hec251 cells stably overexpressing full-length ALK (H251-ALK#8 and #16, two independent clones
of stable cells). Western blot assay detected exogenous ALK protein (220 kDa) and a second protein of approximately 150 kDa (left). Right: note
the strong cytoplasmic ALK staining in the two independent stable cell lines. b Left: phase-contrast images of Hec251 cells stably overexpressing
full-length ALK (H251-ALK#16) and the mock cells treated with 2.5 ng/ml TGF-β1 or 50 ng/ml HGF. Right: western blot analysis for the indicated
proteins in ALK#16 and mock cells. con, control; T, TGF-β1; H, HGF; N, nuclear c Western blot analysis for the indicated proteins in Ishikawa cells
after cotransfection of ALK and shRNAs against ALK. N, nuclear d Analysis of the indicated protein expression levels by western blot assay in Ishikawa
cells after treatment with 20 ng/ml TNF-α for the time shown. N, nuclear e Left: analysis of mRNA levels for the Snail, Slug, and Twist1 genes by real time
RT-PCR in Ishikawa cells following transfection of p65. Middle: analysis of the indicated protein expression by western blot assay in Ishikawa cells after
transfection of p65. Exogenous p65 is indicated by an asterisk in the p65 panel. con, control. Right: Ishikawa cells were transfected with Snail, Slug, and
Twist1 reporter constructs, together with p65. Relative activity was determined based on arbitrary light units of luciferase activity normalized to pRL-TK
activity. The activities of the reporter plus the effector relative to that of the reporter plus empty vector are shown as means ± SDs. The experiment
was performed in duplicate
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as compared to the mock cells. Similar findings were
also observed in the expression ratio of bcl2 relative to
bax (Fig. 5c). These data indicate that overexpression of
full-length ALK abrogates susceptibility to apoptosis
through alteration in expression of Akt and bcl2 in Em
Ca cells.
Associations between ALK expression and the profiles of
its related molecules in UCSs
To confirm the above findings, immunohistochemical
analyses for ALK and its related molecules were car-
ried out using clinical UCS samples. Representative
IHC findings for ALK and its related molecules areillustrated in Fig. 6a. Distinct nuclear staining for
Sox11, N-myc, pAkt, and Twist1 and cytoplasmic
staining for bcl2 were observed in both carcinomat-
ous and sarcomatous components, but there were no
differences in the IHC scores for these markers be-
tween the two components, with the exception of
Twist1 scores (Fig. 6b).
As shown in Table 3, there were positive correlations
among ALK, Sox11, N-myc, and Twist1 scores in UCS
tissues. The bcl2 and pAkt scores were positively corre-
lated with ALK, Sox11, and N-myc scores, and Sox11,
N-myc, and Twist1 scores, respectively. These findings
supports the in vitro results that show the existence of a
Sox11/N-myc/ALK axis and an association of ALK with
Fig. 4 Transcriptional up-regulation of Twist1 gene by the ALK/Akt/NF-κB axis in UCSs. a The Twist1 promoter sequence containing six putative
NF-κB-binding sites. b Various promoter constructs were used for evaluating transcriptional regulation of the Twist1 promoter by p65. Relative
activity was determined based on arbitrary light units of luciferase activity normalized to pRL-TK activity. The activities of the reporter plus the
effector relative to that of the reporter plus empty vector are shown as means ± SDs. The experiment was performed in duplicate. c ChIP assay
shows that p65 is bound to Twist1 promoter regions. d Analysis of the indicated protein expression levels by western blot assay in H251-ALK#16 cells
after transfection of siRNA against NF-kB/p65. KD, knockdown; con, control; N, nuclear
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pression in Ishikawa and H251-ALK#16 cells.
Discussion
The present study clearly provided evidence that full-
length ALK protein without chromosomal rearrangements
was frequently overexpressed in UCSs, particularly in
sarcomatous components. Moreover, the subcellular
localization of ALK immunoreactivity was mostly cyto-
plasmic compartments in UCS cells, as well as in H251-
ALK#16 cells, which showed increased cell proliferation
as compared to the mock cells. Given the evidence that
cytoplasmic localization of ALK-tyrosine kinase domain
promotes cell proliferation in PC12 cells, in contrast to
membrane attachment for control of neurite outgrowth
and proliferation arrest, [37] it appeared that the cytoplas-
mic status of ALK expression may contribute to aggressive
features of UCSs.
Although the ALK mRNA signals appeared to be posi-
tively associated with the immunoreactivity, some UCS
cases exhibited positive ISH signals despite negative
immunoreactivity. This may be due to the difference in
detection sensitivity between the two assays. In addition,
post-transcriptional or post-translational modification of
ALK expression may also exist. In fact, discrepant resultsbetween ALK transcript and protein expression have
been demonstrated in Calas (melanoma) and NCI-H69
(small cell lung carcinoma) cells [38].
Both N-myc and c-myc can induce the proximal pro-
moter activity of the ALK gene through direct inter-
action with the E-boxes in neuroblastoma cells [39]. In
this study, transfection of N-myc, but not c-myc, in-
duced enhancement of ALK promoter activity in Em Ca
cells, independent of E-box status. Further, transcrip-
tion of both ALK and N-myc genes were positively regu-
lated by Sox11, in line with the IHC results showing
positive correlations among the three genes in USC tissues.
In general, overexpression of Sox11, as well as ALK and N-
myc, contributes to the activation of the expression of early
genes that endow cells with general neuronal properties
[34, 38, 39]. Given that UCSs potentially have neuroendo-
crine features, [40] it appears that activation of signal path-
ways containing Sox11, N-myc, and ALK may be linked to
neuronal differentiation in UCSs. This conclusion is also
supported by our findings showing positive correlations of
bcl2 with ALK, Sox11, and N-myc scores in UCSs, since
bcl2 expression is closely associated with neuroendocrine
differentiation in some tumors [41, 42].
In nucleophosmin (NPM)/ALK-transformed cells,
phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which
Fig. 5 Inhibition of apoptosis by ALK/pAkt axis. a After treatment of Hec251 cells stably overexpressing exogenous ALK (H251-ALK#16) with
doxorubicin (Dox) for 48 h, cells undergoing apoptosis (sub-G1) were detected by flow cytometry. The experiments were performed in triplicate, using
independent samples. b Analysis of protein expression levels by western blot assay in the stable cells after treatment with Dox for 48 h. c Values of
endogenous pAkt relative to tAkt protein (upper) and endogenous bcl2 relative to bax protein (lower) were calculated by normalization to β-actin using
NIH ImageJ software
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interaction of NPM-ALK with the p85 subunit of PI3K
[43, 44]. In addition, activation of NF-κB signaling
through phosphorylation of IκB by Akt also serves as a
key factor for the process by regulating the expression of
EMT master-switch transcription factors [35, 45]. In this
study, H251-ALK#16 cells with stable overexpression of
ALK exhibited an enhancement of EMT properties in
response to treatment with EMT inducers, along with
an increase in endogenous pAkt and nuclear p65. In-
creased pAkt and nuclear p65 expression mediated by
transient transfection of ALK was abrogated by cotrans-
fection of the shRNAs against ALK in Ishikawa cells.
Several lines of evidence from our present study sup-
port the conclusion that Twist1 expression is under the
transcriptional control of p65 : i) rapid induction of
Twist1 expression by treatment of cells with TNF-α; ii)
up-regulation of Twist1 expression at both mRNA and
protein levels by transfection of p65 in Ishikawa cells; iii)
activation of the Twist1 promoter by p65 at the proximal
region (−101 to +62 bp), which is independent of NF-
κB-binding sites, suggesting its association with the basictranscriptional machinery at the promoter; iv) decreased
Twist1 expression by knockdown of endogenous p65 in
H251-ALK#16 cells; v) and significant positive correl-
ation of Twist1 score with both ALK and pAkt IHC
scores in clinical UCS samples. Although we could not
demonstrate immunoreactivity for phosphorylated NF-
κB/p65 (pp65) in UCS tissues, because of a lack of the
available antibody, it appears that the ALK-mediated
Akt/NF-κB/Twist1 pathway may participate in an initial
stage that regulates morphological alterations toward the
sarcomatous phenotype in UCSs, since induction of Akt
was found to activate NF-κB/p65-dependent transcription,
probably through repression of IκBα expression [46].
Another interesting finding in this study was that
H251-ALK#16 cells treated with doxorubicin showed a
decrease in the number of apoptotic cells, along with
stabilization of exogenous ALK and increased endogenous
pAkt and bcl2 expression. Given the fact that Akt itself is
able to prevent caspase activation by maintaining mito-
chondrial integrity through regulation of the bcl2 family,
[36, 47] it is likely that the ALK/Akt/bcl2 axis may act as a
modulator of apoptosis in UCSs.
Fig. 6 IHC findings in UCSs. a Staining by HE and IHC for ALK, Sox11, N-myc, pAkt, Twist1, and bcl2 in UCS51 case (indicated by closed boxes and
magnified in the insets). Original magnification, ×100 and × 400 (inset). b IHC scores for ALK, Sox11, N-myc, pAkt, Twist1, and bcl2 in UCSs. The data
shown are means ± SDs
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Our observations suggest some novel functional roles of
ALK in UCSs (Fig. 7). Overexpression of Sox11 and N-
myc causes transcriptional up-regulation of the ALK
gene, which may be associated with the promotion of
neuroendocrine features in UCS cells. The increased
ALK expression triggers activation of downstream trans-
duction cascades containing Akt, NF-κB, Twist1, andTable 3 Correlations among ALK and its related molecules in
uterine carcinosarcomas
ALK Sox11 N-myc pAkt Twist1
r (p) r (p) r (p) r (p) r (p)
Sox11 0.7 * * * *
(<0.0001)
N-myc (0.74) 0.81 * * *
<0.0001 (<0.0001)
pAkt 0.3 0.41 0.57 * *
(0.04) (0.002) (0.0001)
Twist1 0.46 0.5 0.46 0.4 *
(0.0002) (0.0009) (0.003) (0.008)
bcl2 0.45 0.56 0.49 0.1 0.25
(0.005) (0.0009) (0.003) (0.57) (0.13)
Abbreviation: r Spearman’s correlation coefficient
*, not examminedbcl2, resulting in divergent sarcomatous differentiation
driven from carcinomatous components in UCSs through
induction of the EMT process and inhibition of apoptosis.
The conclusion is supported by further investigation using
endometrial carcinoma cell lines with overexpression of
endogenous full-length ALK, since carcinoma cell lines
that naturally harbor full-length ALK are in general ex-
tremely rare.Fig. 7 Schematic representation of ALK signal networks in modulation
of apoptosis and EMT properties in UCSs
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Additional file 1: Figure S1. (A) ChIP assay shows that N-myc is
bound to the proximal region (−126 to +12 bp) of the ALK promoter.
(B) The ALK promoter sequence containing two putative E-boxes (E1
and E2). (C) Various promoter constructs were used for evaluating
transcriptional regulation of the ALK promoter by N-myc. Relative activity
was determined based on arbitrary light units of luciferase activity
normalized to pRL-TK activity. The activities of the reporter plus the
effector relative to that of the reporter plus empty vector are shown
as means ± SDs. The experiment was performed in duplicate. (TIF 725 kb)
Additional file 2: Figure S2. (A) Two independent Hec251 cell lines
stably overexpressing ALK (H251-ALK#8 and #16) and mock cells were
seeded at low density and monitored for growth. The cell numbers
presented are means ± SDs. P0, P3, P5, and P7: 0, 3,5, and 7 days after
passage. (B) Western blot analysis of expression of cyclin A, p21waf1, and
p27kip1 at P6 of cell growth in stable ALK-overexpressing cell lines. (C)
The pNF-κB reporter construct was transfected into H251-ALK#16 cells
treated with 2.5 ng/ml TGF-β1 or 50 ng/ml HGF for 48 h. Relative activity
was determined based on arbitrary light units of luciferase activity normalized
to pRL-TK activity. The activities of the reporter plus the effector relative to
that of the reporter plus empty vector are shown as means ± SDs.
The experiment was performed in duplicate. (D) Various promoter
constructs were used for evaluating transcriptional regulation of the ALK
promoter by TNF-α. (E) The pNF-κB reporter construct, together with the
ALK expression vector, were transfected into Ishikawa cells. (TIF 843 kb)
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